プレスリリース

TLC and Endo Enter Commercialization Agreement

ダウンロード
2021-06-30

TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, and Endo International plc (Nasdaq: ENDP), through its subsidiary Endo Global Development Limited, today announced an agreement for the commercialization of a liposomal product under development by TLC.

Under the terms of the agreement, TLC will be responsible for the development and manufacturing of the product, including obtaining regulatory approval for the use, distribution, promotion and sale of the product in the United States. Upon TLC’s receipt of regulatory approval, Par Sterile Products, Endo’s sterile injectable business, will market, sell and distribute the product on an exclusive basis in the United States. TLC is eligible to receive upfront and subsequent milestone payments as well as a double-digit share of the net profits from product sales in the United States.

“Endo is committed to helping everyone we serve live their best life,” said Scott Sims, Senior Vice President and General Manager, Sterile Injectables of Endo. “We are focused on expanding and enhancing our portfolio and are pleased to be working with TLC, an innovator in the development of novel nanomedicines, on the delivery of medicines that will help hospitals and healthcare systems focus on patient care.”

“Following a series of recent good news, we are happy to be keeping the momentum going with yet another collaboration that combines the strengths of two outstanding companies,” commented TLC President George Yeh. “We are excited to be working with Endo, a company with a long history in injectables and branded therapeutics, making them the perfect fit for TLC. Along with TLC’s expertise and know-how in liposome technology, Endo’s deep commercial experience and market presence are crucial ingredients in our recipe for successful launch and commercialization of our products.”

About Endo International plc

Endo International plc (NASDAQ: ENDP) is a specialty pharmaceutical company committed to helping everyone we serve live their best life through the delivery of quality, life-enhancing therapies. Our decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Together, we boldly transform insights into treatments benefiting those who need them, when they need them. Learn more at www.endo.com or connect with us on LinkedIn.

About TLC

TLC (NASDAQ: TLC, TWO: 4152) is a clinical-stage specialty pharmaceutical company dedicated to the research and development of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD®). TLC’s deep experience with liposome science allows a combination of onset speed and benefit duration, improving active drug concentrations while decreasing unwanted systemic exposures. TLC’s BioSeizer® technology is designed to enable local sustained release of therapeutic agents at the site of disease or injury; its NanoX® active drug loading technology has been proven in two approved drugs and is designed to alter the systemic exposure of a drug, potentially reducing dosing frequency and enhancing distribution of liposome-encapsulated active agents to the desired site. These technologies are versatile in the choice of active pharmaceutical ingredients, and scalable with respect to manufacturing. TLC has a diverse, wholly owned portfolio of therapeutics that target areas of unmet medical need in pain management, ophthalmology, and oncology. TLC is consistently ranked in the top 5% among all listed companies in Taiwan’s Corporate Governance Evaluations. For more information, visit www.tlcbio.com.

戻る